Entity family

Browse drugs

Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.

3articles mentioning drugs

16drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: KSQ-004EX ×

KSQ-004EX

This drug is selected. Its supporting articles are shown below.

Articles mentioning KSQ-004EX

3 articles · page 1 of 1

383 SOCS1 and regnase-1 inactivation enhances functionality and prevents exhaustion of tumor reactive clonotypes in KSQ-004EX eTIL

jitc · abstract · 2025-11-04 · 8 matching annotations

96.4%

KSQ-004EX solid tumors NCT06598371 Tumor Infiltrating Lymphocyte (TIL) therapy tumor

…th autologous tumor. These data support continued evaluation of KSQ-004EX in patients with solid tumors.…

569 A phase 1/2 study of KSQ-004EX: autologous tumor infiltrating lymphocytes, engineered to inactivate genes encoding SOCS1 and regnase-1, in patients with select advanced solid tumors

jitc · abstract · 2025-11-04 · 7 matching annotations

97.3%

KSQ-004EX IL-2 cyclophosphamide Regnase-1 fludarabine SOCS1 melanoma cervical cancer

…ective of Phase 1 is to evaluate the safety and tolerability of KSQ-004EX. In Phase 2, patients will be enrolled in indication-specific c…

253 eCARTM-T: dual-inactivation of SOCS1 and regnase-1 by CRISPR/Cas9 gene editing enhances CAR-T function against solid tumors

jitc · abstract · 2025-11-04 · 1 matching annotations

93.1%

KSQ-004EX solid tumors hematological cancers NCT06598371 hematologic cancers

…g this insight, we developed the engineered TIL (eTIL®) therapy KSQ-004EX, currently in a phase 1 clinical trial ( NCT06598371). Here, we…